

# Hari Nathan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1150051/publications.pdf>

Version: 2024-02-01

109  
papers

5,717  
citations

76196

40  
h-index

79541

73  
g-index

109  
all docs

109  
docs citations

109  
times ranked

7168  
citing authors

#	ARTICLE	IF	CITATIONS
1	High Socioeconomic Deprivation and Coronary Artery Bypass Grafting Outcomes: Insights From Michigan. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1962-1970.	0.7	10
2	Incremental Spending Associated with Low-Value Treatments in Older Women with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 1051-1059.	0.7	7
3	Variation in Surgical Spending Among the Highest Quality Hospitals for Cancer Surgery. <i>Annals of Surgery</i> , 2022, 276, e728-e734.	2.1	5
4	Surgical quality assurance at expanding health networks: A qualitative study. <i>Surgery</i> , 2022, , .	1.0	0
5	Statewide Episode Spending Variation of Mastectomy for Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2022, 234, 14-23.	0.2	4
6	Association of Dual Medicare and Medicaid Eligibility With Outcomes and Spending for Cancer Surgery in High-Quality Hospitals. <i>JAMA Surgery</i> , 2022, 157, e217586.	2.2	9
7	Area Deprivation and Medicare Spending for Coronary Artery Bypass Grafting: Insights From Michigan. <i>Annals of Thoracic Surgery</i> , 2022, 114, 1291-1297.	0.7	4
8	Facility-Level Variation of Low-Value Breast Cancer Treatments in Older Women with Early-Stage Breast Cancer: Analysis of a Statewide Claims Registry. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
9	ASO Visual Abstract: Facility-Level Variation of Low-Value Breast Cancer Treatments in Older Women with Early-Stage Breast Cancer: Analysis of a Statewide Claims Registry. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
10	Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1805-1814.	0.9	7
11	Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis. <i>Cancer</i> , 2021, 127, 1266-1274.	2.0	9
12	Variations in surgical spending within hospital systems for complex cancer surgery. <i>Cancer</i> , 2021, 127, 586-597.	2.0	7
13	Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 273, 587-594.	2.1	39
14	Immunotherapy for pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 751-759.	0.8	18
15	The Affordable Care Act at 10 Years: Evaluating the Evidence and Navigating an Uncertain Future. <i>Journal of Surgical Research</i> , 2021, 263, 102-109.	0.8	11
16	Patterns and Determinants of Low-Value Preoperative Testing in Michigan. <i>JAMA Internal Medicine</i> , 2021, 181, 1115.	2.6	17
17	Strengths and Limitations of Registries in Surgical Oncology Research. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2989-2996.	0.9	4
18	Wide Variation in Surgical Spending Within Hospital Systems. <i>Annals of Surgery</i> , 2021, 274, e1078-e1084.	2.1	8

#	ARTICLE	IF	CITATIONS
19	Abstract 10506: Cardiac Rehabilitation Visits Have Not Recovered to Pre-Pandemic Levels. <i>Circulation</i> , 2021, 144, .	1.6	0
20	Abstract 10513: Early Follow-Up After Heart Failure Hospitalizations Remains Low and Variable Across Hospitals: Insights from the Michigan. <i>Circulation</i> , 2021, 144, .	1.6	0
21	Local Referral of High-Risk Pancreatectomy Patients to Improve Surgical Outcomes and Minimize Travel Burden. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 882-889.	0.9	3
22	Employee Healthcare Travel Programs. <i>Annals of Surgery</i> , 2020, 271, 815-816.	2.1	2
23	Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice. <i>Gastroenterology</i> , 2020, 158, 1417-1432.e11.	0.6	48
24	Appendiceal Neuroendocrine Tumors: Does Colon Resection Improve Outcomes?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2121-2126.	0.9	5
25	The Quality of Surgical Care at Hospitals Associated With America's Highest-rated Medical Centers. <i>Annals of Surgery</i> , 2020, 271, 862-867.	2.1	7
26	Sources of Hospital Variation in Postacute Care Spending After Cardiac Surgery. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006449.	0.9	13
27	Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. <i>Nature Cancer</i> , 2020, 1, 1097-1112.	5.7	234
28	Association of Surgeon Case Numbers of Pancreaticoduodenectomies vs Related Procedures With Patient Outcomes to Inform Volume-Based Credentialing. <i>JAMA Network Open</i> , 2020, 3, e203850.	2.8	22
29	Recanalization of the bile duct by using percutaneous and endoscopic methods after iatrogenic injury. <i>VideoGIE</i> , 2020, 5, 308-310.	0.3	3
30	Local Referral of High-risk Patients to High-quality Hospitals. <i>Annals of Surgery</i> , 2020, 271, 1065-1071.	2.1	18
31	Challenges and Opportunities for the Academic Mission Within Expanding Health Systems. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	2.1	2
32	Early Impact of Medicare Accountable Care Organizations on Inpatient Surgical Spending. <i>Annals of Surgery</i> , 2019, 269, 191-196.	2.1	31
33	Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?. <i>Journal of Surgical Oncology</i> , 2019, 120, 919-925.	0.8	10
34	Association of Discretionary Hospital Volume Standards for High-risk Cancer Surgery With Patient Outcomes and Access, 2005-2016. <i>JAMA Surgery</i> , 2019, 154, 1005.	2.2	62
35	Regional and racial variations in the utilization of endoscopic retrograde cholangiopancreatography among pancreatic cancer patients in the United States. <i>Cancer Medicine</i> , 2019, 8, 3420-3427.	1.3	10
36	Hospital factors strongly influence robotic use in general surgery. <i>Surgery</i> , 2019, 166, 867-872.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Centralization of High-Risk Cancer Surgery Within Existing Hospital Systems. <i>Journal of Clinical Oncology</i> , 2019, 37, 3234-3242.	0.8	88
38	Variation in Surgical Outcomes Across Networks of the Highest-Rated US Hospitals. <i>JAMA Surgery</i> , 2019, 154, 510.	2.2	34
39	Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2225-2231.	0.9	10
40	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. <i>American Surgeon</i> , 2019, 85, 1334-1340.	0.4	7
41	Association of adjuvant radiotherapy with survival after margin-negative resection of pancreatic ductal adenocarcinoma: a propensity-matched national cancer database (ncdb) analysis. <i>Hpb</i> , 2019, 21, S310.	0.1	4
42	Who Will be the Costliest Patients? Using Recent Claims to Predict Expensive Surgical Episodes. <i>Medical Care</i> , 2019, 57, 869-874.	1.1	3
43	Gastric carcinoids: Does type of surgery or tumor affect survival?. <i>American Journal of Surgery</i> , 2019, 217, 937-942.	0.9	11
44	The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8â€institution study from the US Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2019, 119, 5-11.	0.8	5
45	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>JAMA Network Open</i> , 2019, 2, e186839.	2.8	14
46	Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. <i>JAMA Surgery</i> , 2019, 154, 134.	2.2	54
47	Hot Spotting as a Strategy to Identify High-Cost Surgical Populations. <i>Annals of Surgery</i> , 2019, 269, 453-458.	2.1	21
48	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. <i>American Surgeon</i> , 2019, 85, 1334-1340.	0.4	3
49	Commentary on Brief Clinical Report. <i>Annals of Surgery</i> , 2018, 267, e17.	2.1	2
50	Strategies for Reducing Population Surgical Costs in Medicare. <i>Annals of Surgery</i> , 2018, 267, 878-885.	2.1	9
51	Hospital quality, patient risk, and Medicare expenditures for cancer surgery. <i>Cancer</i> , 2018, 124, 826-832.	2.0	14
52	Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis. <i>Journal of Surgical Oncology</i> , 2018, 117, 644-650.	0.8	108
53	Spatial and phenotypic immune profiling of metastatic colon cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	73
54	Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28. <i>Journal of Surgical Research</i> , 2018, 232, 570-577.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Quality Measurement and Pay for Performance. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 621-632.	0.6	2
56	Hospital Teaching Status and Medicare Expenditures for Complex Surgery. <i>Annals of Surgery</i> , 2017, 265, 502-513.	2.1	43
57	Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 2023-2030.	0.7	230
58	Quality Accounting. <i>Annals of Surgery</i> , 2017, 265, 1051-1052.	2.1	5
59	Travel Burdens of Selective Referral for Surgical Patients. <i>Annals of Surgery</i> , 2017, 265, e26.	2.1	2
60	Treating Perioperative Complications. <i>JAMA Surgery</i> , 2017, 152, 959.	2.2	1
61	Impact of the Hospital Readmission Reduction Program on Surgical Readmissions Among Medicare Beneficiaries. <i>Annals of Surgery</i> , 2017, 266, 617-624.	2.1	69
62	Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. <i>Hepatology</i> , 2017, 65, 122-133.	3.6	82
63	Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. <i>Cancer</i> , 2017, 123, 568-575.	2.0	39
64	Postoperative Complications and Long-Term Survival After Complex Cancer Resection. <i>Annals of Surgical Oncology</i> , 2017, 24, 638-644.	0.7	66
65	Medicare's Shift to Mandatory Alternative Payment Models. <i>JAMA Surgery</i> , 2017, 152, 125.	2.2	12
66	Successful Loop Snare Salvage of Contralateral Glue Migration during Portal Vein Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1310-1312.	0.2	3
67	Assessing the Effect of the Affordable Care Act on Surgical Populations. <i>JAMA Surgery</i> , 2016, 151, e163635.	2.2	0
68	Treatment of Colorectal Liver Metastases: None of Us Is As Smart As All of Us. <i>Journal of Oncology Practice</i> , 2016, 12, 42-43.	2.5	0
69	Variation in Medicare Expenditures for Treating Perioperative Complications. <i>JAMA Surgery</i> , 2016, 151, e163340.	2.2	65
70	Opportunities for Surgical Leadership in Managing Population Health Costs. <i>Annals of Surgery</i> , 2016, 264, 909-910.	2.1	3
71	National trends in resection of cystic lesions of the pancreas. <i>Hpb</i> , 2016, 18, 375-382.	0.1	5
72	A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 899-904.	0.9	20

#	ARTICLE	IF	CITATIONS
73	Hospital Volume, Complications, and Cost of Cancer Surgery in the Elderly. <i>Journal of Clinical Oncology</i> , 2015, 33, 107-114.	0.8	97
74	Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma: A National Perspective. <i>Journal of the American College of Surgeons</i> , 2014, 218, 196-205.	0.2	75
75	Clinical Decision-Making by Gastroenterologists and Hepatologists for Patients with Early Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 1844-1851.	0.7	9
76	Pharmacologic Prophylaxis, Postoperative INR, and Risk of Venous Thromboembolism after Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 295-303.	0.9	24
77	Referral Patterns and Treatment Choices for Patients with Hepatocellular Carcinoma: A United States Population-Based Study. <i>Journal of the American College of Surgeons</i> , 2013, 217, 896-906.	0.2	47
78	Influence of Nonclinical Factors on Choice of Therapy for Early Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 448-456.	0.7	23
79	Influence of Patient, Physician, and Hospital Factors on 30-Day Readmission Following Pancreatoduodenectomy in the United States. <i>JAMA Surgery</i> , 2013, 148, 1095.	2.2	137
80	Surgical Therapy for Early Hepatocellular Carcinoma in the Modern Era. <i>Annals of Surgery</i> , 2013, 258, 1022-1027.	2.1	59
81	Outcomes From IBD-Associated and Non-IBD-Associated Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 270-277.	0.7	32
82	Treating Patients with Colon Cancer Liver Metastasis: A Nationwide Analysis of Therapeutic Decision Making. <i>Annals of Surgical Oncology</i> , 2012, 19, 3668-3676.	0.7	26
83	National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. <i>Cancer</i> , 2012, 118, 1838-1844.	2.0	49
84	Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. <i>Cancer</i> , 2012, 118, 2674-2681.	2.0	132
85	Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant Therapy. <i>Journal of the American College of Surgeons</i> , 2012, 214, 33-45.	0.2	157
86	Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment. <i>Journal of Clinical Oncology</i> , 2011, 29, 3140-3145.	0.8	615
87	Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. <i>Hpb</i> , 2011, 13, 473-482.	0.1	140
88	Variation in Lymph Node Assessment After Colon Cancer Resection: Patient, Surgeon, Pathologist, or Hospital?. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 471-479.	0.9	74
89	Staging of intrahepatic cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 269-273.	1.0	53
90	Prognostication for Trunk and Retroperitoneal Sarcomas. <i>Annals of Surgery</i> , 2010, 252, 201-202.	2.1	0

#	ARTICLE	IF	CITATIONS
91	Primary liver cancer: intrahepatic cholangiocarcinoma emerges from the shadows. Updates in Surgery, 2010, 62, 5-9.	0.9	14
92	National Trends in the Management and Survival of Surgically Managed Gallbladder Adenocarcinoma Over 15 Years: A Population-Based Analysis. Journal of Gastrointestinal Surgery, 2010, 14, 1578-1591.	0.9	102
93	Conditional Survival after Surgical Resection of Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 949 Patients. Journal of the American College of Surgeons, 2010, 210, 755-764.	0.2	119
94	Adjuvant Chemoradiation Therapy for Adenocarcinoma of the Distal Pancreas. Annals of Surgical Oncology, 2010, 17, 3112-3119.	0.7	28
95	Needlestick Injuries Among Medical Students: Incidence and Implications. Academic Medicine, 2009, 84, 1815-1821.	0.8	64
96	The Volume-Outcomes Effect in Hepato-Pancreato-Biliary Surgery: Hospital Versus Surgeon Contributions and Specificity of the Relationship. Journal of the American College of Surgeons, 2009, 208, 528-538.	0.2	186
97	Perioperative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: A population-based perspective. Journal of Surgical Oncology, 2009, 99, 87-92.	0.8	67
98	Comparative performances of staging systems for early hepatocellular carcinoma. Hpb, 2009, 11, 382-390.	0.1	24
99	A Proposed Staging System for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2009, 16, 14-22.	0.7	294
100	Risk Factors for Pancreatic Leak After Distal Pancreatectomy. Annals of Surgery, 2009, 250, 277-281.	2.1	129
101	Trends in the Quality of Highly Cited Surgical Research Over the Past 20 Years. Annals of Surgery, 2009, 249, 162-167.	2.1	48
102	Predictors of Survival After Resection of Retroperitoneal Sarcoma. Annals of Surgery, 2009, 250, 970-976.	2.1	137
103	Predictors of Survival After Resection of Early Hepatocellular Carcinoma. Annals of Surgery, 2009, 249, 799-805.	2.1	239
104	Operative Mortality After Hepatic Resection: Are Literature-Based Rates Broadly Applicable?. Journal of Gastrointestinal Surgery, 2008, 12, 842-851.	0.9	137
105	Limitations of Claims and Registry Data in Surgical Oncology Research. Annals of Surgical Oncology, 2008, 15, 415-423.	0.7	209
106	Choledochal Cyst Disease in Children and Adults: A 30-Year Single-Institution Experience. Journal of the American College of Surgeons, 2008, 206, 1000-1005.	0.2	120
107	Racial Disparity in Surgical Mortality after Major Hepatectomy. Journal of the American College of Surgeons, 2008, 207, 312-319.	0.2	53
108	Trends in Survival after Surgery for Cholangiocarcinoma: A 30-Year Population-Based SEER Database Analysis. Journal of Gastrointestinal Surgery, 2007, 11, 1488-1497.	0.9	214

#	ARTICLE	IF	CITATIONS
109	Benign Pneumatosis Intestinalis in the Setting of Celiac Disease. Journal of Gastrointestinal Surgery, 2006, 10, 890-894.	0.9	17